bluebird bio: Beaten Down Biotech With Possible Long-Term Potential [Seeking Alpha]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Seeking Alpha
DNY59/E+ via Getty Imagesbluebird bio, Inc. (NASDAQ:BLUEevents over the last few years. However, there is potential to invest in this name in a speculative fashion.There are several reasons why I believe this to be the case. The first reason is that it only trades at around $3.60 per share, which means the downside is limited. More importantly, there is potential for an explosive recovery. It still is a speculative situation, but it expects up to 2 possible FDA approvals for its gene therapies in 2022.Then, there is the possibility of a 3rd FDA approved gene therapy candidate from its pipeline in 2023 as well. The 3 gene therapies in question are beti-cel for beta-thalassemia, eli-cel for cerebral adrenoleukoodystrophy and lovo-cel for sickle cell disease. The possible BLA filing for lovo-cel for sickle-cell disease is expected Q1 of 2023, from there FDA approval would come later in 2023 or early 2024. The FDA has set PDUFA dates of August 19, 2022 for beti-cel for beta thalassemia an
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $94.00 to $91.00. They now have a "neutral" rating on the stock.MarketBeat
- BioMarin stock falls 9% in wake of Q1 report, pipeline updates [Seeking Alpha]Seeking Alpha
- BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Scotiabank from $83.00 to $85.00. They now have a "sector perform" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.MarketBeat
BMRN
Earnings
- 4/24/24 - Beat
BMRN
Sec Filings
- 4/24/24 - Form 8-K
- 4/23/24 - Form 8-K
- 4/15/24 - Form 4
- BMRN's page on the SEC website